secwatch / observer

8-K filed November 1, 2024, 7:59 PM ET ticker IDAI CIK 0001718939

regulatory confidence high sentiment positive materiality 0.70

T Stamp regains Nasdaq minimum equity compliance; stockholders' equity > $5M

T Stamp Inc

Converted $2M promissory notes into 4,597,701 shares at $0.435/share in July 2024.
Granted non-exclusive patent license to Boumarang for a $5M prepaid warrant (August 2024).
Sold warrants and received exercise proceeds; net proceeds $183,662 after fees and payment.
Company now believes stockholders' equity exceeds $5M, above Nasdaq's $2.5M minimum.
Nasdaq will monitor compliance at next periodic report; failure could lead to delisting.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001718939-24-000184
form_type: 8-K
ticker: IDAI
cik: 0001718939
company_name: T Stamp Inc
filed_at: 2024-11-01T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.350541+00:00
generated_at: 2026-05-30T06:59:22.410658+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001718939-24-000184
json_url: https://secwatch.observer/filing/0001718939-24-000184.json
markdown_url: https://secwatch.observer/filing/0001718939-24-000184.md
text_url: https://secwatch.observer/filing/0001718939-24-000184.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1718939/000171893924000184/0001718939-24-000184-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1718939/000171893924000184/idai-20241101.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

PDSB

PDS Biotech regains Nasdaq minimum bid price compliance as of June 2, 2026

PDS Biotechnology Corp June 2, 2026, 3:35 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA approves Afrezza for pediatric diabetes patients ages 6+

MANNKIND CORP June 2, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VERA

Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026

Vera Therapeutics, Inc. June 2, 2026, 7:05 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

TXNM

TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables

TXNM ENERGY INC June 1, 2026, 5:54 PM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VYGR

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc. June 1, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

EXFY

Expensify regains Nasdaq minimum bid price compliance

Expensify, Inc. May 29, 2026, 5:15 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001718939-24-000184

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.